Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA synthetase short chain family member 1 (ACSS1) is a mitochondrial enzyme that catalyzes the conversion of acetate and other short-chain fatty acids into acetyl-CoA, a central metabolic intermediate[1][2][5]. Acetyl-CoA produced by ACSS1 is primarily used for energy production and is particularly vital for cellular energy homeostasis during ketogenic conditions, such as fasting or carbohydrate deprivation[1]. While acetate is its preferred substrate, the enzyme can also utilize propionate with much lower affinity. ACSS1 is involved in metabolic pathways like the TCA cycle and plays a role in thermogenesis. Diseases associated with mutations in ACSS1 include Cystoisosporiasis and Canavan disease[1][5]. The gene is located in the mitochondrial matrix and alternative splice variants exist[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA synthetase short chain family member 1 (ACSS1).